Vector Science and Therapeutics Corp. is a Canada-based company. The Company develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions. The Company's product platforms and applications include Laparoscopic Atomizing Solution System (LASS) and Biomechanical Transdermal Device (BTP). The LASS Platform is an atomizing solution system designed to deliver therapeutics/anesthetics in a manner that infiltrates tissue to have a specific therapeutic effect. VectorMist is a catheter-based system designed for targeted delivery of atomized therapeutics directly into the surgical field during laparoscopic procedures. Vector BTP is an electrical biomechanical platform that functions as both a standalone therapeutic intervention and a drug delivery platform competing directly with sustained acoustic medicine devices and pulsed electromagnetic field devices in the regenerative and sports medicine segments.

Employees

Sector

Investment Holding Companies

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	CA$1.830	+2.81%	128,748
20/08/26	CA$1.780	-11.00%	84,500
19/08/26	CA$2.000	0.00%	113,362
18/08/26	CA$2.000	-6.98%	206,351
17/08/26	CA$2.150	-1.38%	238,667

Delayed Quote Toronto S.E.

More quotes

Market Closed - Toronto S.E. 22:59:59 21/08/2026 +03			5-day change	1st Jan Change
1.830 ^CAD	+2.81%		-16.06%	+3,560.00%

08-20	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	CI
08-17	Vector Science and Therapeutics Signs Amended 10-Year Manufacturing and Testing Agreement	MT

Market Cap	208M 178M 167M 152M 286M 19.88B 290M 1.97B 767M 9.99B 780M 763M 33.04B	P/E 2024 *	-	P/E 2025	-0.29x
Enterprise Value	205M 176M 164M 150M 282M 19.61B 286M 1.94B 757M 9.85B 770M 753M 32.58B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	79.62%	Yield 2024 *	-	Yield 2025	-

08-20	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	CI
08-17	Vector Science and Therapeutics Signs Amended 10-Year Manufacturing and Testing Agreement	MT
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC	CI
07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-25	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization	MT
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
07-17	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
07-15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
07-08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
07-07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
06-30	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI
06-12	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform	CI

08-20	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	AQ
08-19	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings	AQ
07-27	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-25	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ

Vector Science and Therapeutics Corp. Stock

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Valuation: Vector Science and Therapeutics Corp.

Chart: Vector Science and Therapeutics Corp.

Latest news : Vector Science and Therapeutics Corp.

Press Releases: Vector Science and Therapeutics Corp.

Quotes and Performance

Course Extremes

Latest insider transactions

Shell Companies

Financials

Company Profile

Quotes

1 day	+2.81%
1 week	-16.06%
Current month	+13.66%
1 month	+18.06%
3 months	+50.00%
6 months	+3,560.00%
Current year	+3,560.00%

1 week	1.76	2.24
1 month	1.5	2.24
Current year	0.35	2.65
1 year	0.35	2.65
3 years	0.03	2.65
5 years	0.03	2.65
10 years	0.03	2.65

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VECTOR SCIENCE AND THERAPEUTICS CORP.	+2.81%	-16.06%	+3,560.00%	+2,950.00%	208M
CHURCHILL CAPITAL CORP XI	+3.55%	-14.65%	-	-	812M
CENTIEL AG	-7.45%	-7.18%	+289.16%	-70.90%	658M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.10%	-	-	646M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.39%	+0.29%	-	-	600M
CHURCHILL CAPITAL CORP XII	-0.74%	-0.33%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	-0.48%	-0.77%	+2.17%	-	591M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.52%	+1.21%	-	-	578M
CHURCHILL CAPITAL CORP XIII	0.00%	+0.67%	-	-	508M
Average	-0.24%	-4.09%	+1,283.78%	+1,439.55%	577.24M
Weighted average by Cap.	-0.40%	-3.73%	+639.43%	+654.45%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-